Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Product substitution issue? 113 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 113 reports of Product substitution issue have been filed in association with INFLIXIMAB (Renflexis). This represents 0.1% of all adverse event reports for INFLIXIMAB.

113
Reports of Product substitution issue with INFLIXIMAB
0.1%
of all INFLIXIMAB reports
1
Deaths
14
Hospitalizations

How Dangerous Is Product substitution issue From INFLIXIMAB?

Of the 113 reports, 1 (0.9%) resulted in death, 14 (12.4%) required hospitalization, and 4 (3.5%) were considered life-threatening.

Is Product substitution issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 113 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Product substitution issue?

AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (2,832) BUPROPION (1,578) METHYLPHENIDATE (1,408) CLONAZEPAM (1,288) LAMOTRIGINE (979) ALBUTEROL (864) LEVOTHYROXINE (803) DULOXETINE (766) ESTRADIOL (692) SERTRALINE (636)

Which INFLIXIMAB Alternatives Have Lower Product substitution issue Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Product substitution issue Reports All Drugs Causing Product substitution issue INFLIXIMAB Demographics